Biocept, Inc.
BIOCQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $26 | $61 | $27 | $6 |
| % Growth | -57.8% | 123% | 396.7% | – |
| Cost of Goods Sold | $28 | $38 | $21 | $11 |
| Gross Profit | -$3 | $23 | $6 | -$5 |
| % Margin | -10% | 38.3% | 22.3% | -98.6% |
| R&D Expenses | $6 | $5 | $5 | $5 |
| G&A Expenses | $16 | $13 | $10 | $7 |
| SG&A Expenses | $23 | $21 | $16 | $13 |
| Sales & Mktg Exp. | $7 | $8 | $6 | $6 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $29 | $26 | $22 | $18 |
| Operating Income | -$32 | -$2 | -$15 | -$23 |
| % Margin | -123.7% | -3.9% | -56.3% | -417.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$2 | -$2 |
| Pre-Tax Income | -$32 | -$3 | -$18 | -$25 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$32 | -$3 | -$18 | -$25 |
| % Margin | -124.1% | -4.6% | -64.8% | -454.7% |
| EPS | -56.78 | -5.73 | -45.1 | -365.01 |
| % Growth | -890.9% | 87.3% | 87.6% | – |
| EPS Diluted | -56.78 | -5.73 | -45.1 | -365.01 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$30 | -$1 | -$17 | -$24 |
| % Margin | -117% | -1.4% | -60.3% | -436.2% |